Three Poster Presentations Demonstrate The Long-Term Efficacy of Mavorixafor in Primary Immunodeficiencies
source: pixabay.com

Three Poster Presentations Demonstrate The Long-Term Efficacy of Mavorixafor in Primary Immunodeficiencies

X4 Pharmaceuticals Inc. has recently published data from 3 different posters which were presented at the American Society of Hematology (ASH) Annual Meeting in Georgia. You can read the full…

Continue Reading Three Poster Presentations Demonstrate The Long-Term Efficacy of Mavorixafor in Primary Immunodeficiencies
AI Vastly Improves Enrollment in Rare Disease Clinical Trials
https://pixabay.com/en/technology-robot-human-hand-2025795/

AI Vastly Improves Enrollment in Rare Disease Clinical Trials

Clinical trial recruitment has always been challenging. It is especially challenging for therapies being tested for rare diseases, an already small population. Clinical trials for rare diseases are small out…

Continue Reading AI Vastly Improves Enrollment in Rare Disease Clinical Trials
Experimental WHIM Syndrome Treatment Gets FDA Fast Track Designation
source: pixabay.com

Experimental WHIM Syndrome Treatment Gets FDA Fast Track Designation

According to a story from GlobeNewswire, the biopharmaceutical company X4 Pharmaceuticals, Inc. has just announced that the US Food and Drug Administration (FDA) has granted its investigational product candidate mavorixafor…

Continue Reading Experimental WHIM Syndrome Treatment Gets FDA Fast Track Designation

Breakthrough Therapy Designation Given to Investigative WHIM Syndrome Treatment

WHIM Syndrome WHIM syndrome is a form of primary immunodeficiency. It is caused by a mutation in the CXCR4 gene. WHIM stands for Warts, Hypogammaglobulinemia, Infections, and Myelokathexis. Throughout their…

Continue Reading Breakthrough Therapy Designation Given to Investigative WHIM Syndrome Treatment
Possible Treatment for WHIM Syndrome Earns Orphan Drug Designation in the EU
Free-Photos / Pixabay

Possible Treatment for WHIM Syndrome Earns Orphan Drug Designation in the EU

According to a story from home.suddenlink.net, the biopharmaceutical company X4 Pharmaceuticals recently announced that the European Commission has granted Orphan Drug designation to the company's lead investigational drug candidate, mavorixafor.…

Continue Reading Possible Treatment for WHIM Syndrome Earns Orphan Drug Designation in the EU
Company Starts up Late Stage Trial Testing Experimental WHIM Syndrome Treatment
mwooten / Pixabay

Company Starts up Late Stage Trial Testing Experimental WHIM Syndrome Treatment

According to a story from BioPortfolio, the biopharmaceutical company X4 Pharmaceuticals, Inc. has recently initiated a phase 3 clinical trial that is testing its current lead product candidate mavorixafor. This…

Continue Reading Company Starts up Late Stage Trial Testing Experimental WHIM Syndrome Treatment

Companies Announce Plan to Offer Free Genetic Tests for Patients With Suspected WHIM Syndrome or Severe Congenital Neutropenia

According to a story from Business Wire, the biopharmaceutical company X4 Pharmaceuticals, Inc. and the medical genetics company Invitae Corporation have recently announced that they have come into a parternship…

Continue Reading Companies Announce Plan to Offer Free Genetic Tests for Patients With Suspected WHIM Syndrome or Severe Congenital Neutropenia

X4 Pharmaceuticals Reports Positive Phase 2 Results for WHIM Syndrome Drug

According to an article published by Biospace, X4 Pharmaceuticals, based in Cambridge, Massachusetts, has recently announced successful phase two results in clinical trials for their experimental drug X4P-001. The drug…

Continue Reading X4 Pharmaceuticals Reports Positive Phase 2 Results for WHIM Syndrome Drug
Experimental Treatment for WHIM Syndrome Gets Orphan Drug Designation
jarmoluk / Pixabay

Experimental Treatment for WHIM Syndrome Gets Orphan Drug Designation

According to a story from BioSpace, the biotechnology company X4 Pharmaceuticals recently announced that the US Food and Drug Administration (FDA) has given Orphan Drug designation to the company's investigational…

Continue Reading Experimental Treatment for WHIM Syndrome Gets Orphan Drug Designation

Interim Results From a Study of a Potential Treatment For WHIM Syndrome Have Been Released

Clinical data from a Phase 2 study of the experimental drug X4P-001-RD for the treatment of WHIM syndrome has been announced at the European Hematology Association’s 23rdCongress in Stockholm. The…

Continue Reading Interim Results From a Study of a Potential Treatment For WHIM Syndrome Have Been Released